|
Status |
Public on Jan 09, 2016 |
Title |
pre-vaccination blood sample from donor 1062 |
Sample type |
RNA |
|
|
Source name |
Blood sample from donor 1062
|
Organism |
Homo sapiens |
Characteristics |
tissue: Blood donor: 1062 donor set: 1 vaccination time: pre-vaccination visit number: V2 hepatitis b average concentration (unit): mIU/mL hepatitis b average concentration (pre-vax): <5 hepatitis b average concentration (post-vax): <5 age: 70
|
Extracted molecule |
total RNA |
Extraction protocol |
Samples are processed in parallel in 96-well plates to minimize potential variation. Reaction purification is achieved using magnetic binding beads for cDNA and Qiagen RNeasy kits for cRNA purification.
|
Label |
biotin
|
Label protocol |
Nugen amplification protocol
|
|
|
Hybridization protocol |
GeneChip microarrays are loaded with the fragmented target sample/hybridization buffer mix using standard manual techniques. Arrays are hybridized for 18 hours at 45oC with vigorous mixing. Unbound sample is removed and staining is accomplished through the binding of streptavidin conjugated phycoerythrin to the hybridized target. Excess label is removed. Washing and staining steps are performed by the Affymetrix FS450 fluidics station using standard protocols.
|
Scan protocol |
Arrays are scanned using a GeneChip Scanner 3000 7G with a 48 array autoloader. The scanner maintains the optimal temperature for the arrays prior to and during scanning.
|
Description |
pre-vaccination blood transcriptional profilling
|
Data processing |
The data were analyzed with preprocessed in R using the RMA normalization method.
|
|
|
Submission date |
Feb 10, 2015 |
Last update date |
Jan 10, 2016 |
Contact name |
Slim Fourati |
E-mail(s) |
[email protected]
|
Organization name |
Northwestern University
|
Department |
Medicine
|
Lab |
Fourati
|
Street address |
300 E Superior St
|
City |
Chicago |
State/province |
Illinois |
ZIP/Postal code |
60611 |
Country |
USA |
|
|
Platform ID |
GPL15048 |
Series (1) |
GSE65834 |
Transcriptional profiling of HBV-naïve subjects before vaccination against Hepatitis A/B viruses, Diphtheria/Tetanus toxoids and Cholera. |
|